Androgen Deprivation Therapy and Radiation

Chapter 11

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of radiation with androgen deprivation therapy in men with prostate cancer.

Chapter 1

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Chapter 2

Targeted Agents (cont.)

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.

Chapter 3

Radium-223

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.

Chapter 4

Chemotherapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the role of cytotoxic chemotherapy in treatment of castration resistant prostate cancer and metastatic castration resistant prostate cancer.

Chapter 5

Immunotherapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss immunotherapy approaches to treatment of metastatic castration resistant prostate cancer.

Chapter 6

Treatment Sequencing

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal sequencing of therapies in metastatic castration resistant prostate cancer.

Chapter 7

Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss androgen deprivation therapy in advanced/metastatic prostate cancer.

Chapter 8

Duration of Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal duration of androgen deprivation in the treatment of high-risk and very high-risk locally advanced prostate cancer.

Chapter 9

Docetaxel in Combination with Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of docetaxel in combination with androgen deprivation therapy in men with prostate cancer.

Chapter 10

Androgen Deprivation Therapy Resistance

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss resistance to androgen deprivation therapy in men with prostate cancer.

Chapter 12

Predictions for the Future

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss their predictions for advances in the treatment of men with prostate cancer in next five years.

Speakers
Philip Kantoff, MD Philip Kantoff, MD, Director of the Lank Center for Genitourinary Oncology, Vice Chair and Chief of the Division of Solid Tumor Oncology, Department of Medical Oncology at the Dana-Farber Cancer Institute and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School in Boston, Massachusetts
Andrew J. Armstrong, MD Andrew J. Armstrong, MD, Associate Professor of Medicine and Surgery, Associate Director for Clinical Research in Genitourinary Oncology at the Duke Cancer Institute, Divisions of Medical Oncology and Urology at Duke University in Durham, North Carolina
A. Oliver Sartor, MD A. Oliver Sartor, MD, Medical Director at the Tulane Cancer Center; C.E. and Bernadine Laborde Professor of Cancer Research; and Professor in the Departments of Medicine and Urology at Tulane Medical School in New Orleans, Louisiana
William K. Oh, MD William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; Dr. Ezra M. Greenspan Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine; and Associate Director for Clinical Research at The Tisch Cancer Institute in New York, New York

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs